Washington, D.C. — House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA) and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA) announced an oversight subcommittee hearing titled “At What Cost: Oversight of How the IRA's Price Setting Scheme Means Fewer Cures for Patients.”

"Patients across America are relying on medical innovators to develop new treatments and cures. Since the so-called 'Inflation Reduction Act' was signed into law by President Biden, at least two dozen drug makers have scaled back their research and development priorities, raising concerns about the future availability of innovative treatments. In addition to the law’s chilling effect on medical innovation, the act's ‘negotiation’ provisions have sparked significant constitutional debates, with several challenges currently under legal review. This hearing will give our members an opportunity to hear from experts and stakeholders about how the law has already affected new treatments and cures for patients and what we might expect in the coming months,” said Chairs Rodgers and Griffith. 

Subcommittee on Oversight and Investigations hearing titled “At What Cost: Oversight of How the IRA's Price Setting Scheme Means Fewer Cures for Patients.” 

WHAT: A subcommittee hearing to discuss oversight of the Biden administration’s price setting scheme. 

DATE: Wednesday, September 20, 2023 

TIME: 2:00 PM ET 

LOCATION: 2123 Rayburn House Office Building    

WITNESS: Witnesses will be announced and are by invitation only.   

This notice is at the direction of the Chair. The hearing will be open to the public and press and will be live streamed online at https://energycommerce.house.gov/. If you have any questions concerning the hearing, please contact Lauren Eriksen with the Committee staff at Lauren.Eriksen@mail.house.gov. If you have any press-related questions, please contact Christopher Krepich at Christopher.Krepich@mail.house.gov.